October 21, 2010
Current scientific publications by respected academic research groups show that the regulatory T-cells in particular play a central part in the development and progression of MS; impairment of their function in the patient appears to be causally linked with the disease. The monoclonal antibody BT-061 specifically activates regulatory T-cells. The pre-clinical data that have now been obtained show that BT-061 reinforces the function of regulatory T-cells derived from MS patients.
Monoclonal antibody BT-061 shows potential in the indication multiple sclerosis
– Biotest generates positive pre-clinical data in the indication multiple sclerosis
– Further development in this indication supported by the German Federal Ministry of Education and Research in the framework of the ´Neu² Konsortium´
Dreieich, 21. October 2010. Biotest has obtained positive pre-clinical data indicating the potential of BT-061 for the treatment of multiple sclerosis (MS).
Current scientific publications by respected academic research groups show that the regulatory T-cells in particular play a central part in the development and progression of MS; impairment of their function in the patient appears to be causally linked with the disease. The monoclonal antibody BT-061 specifically activates regulatory T-cells. The pre-clinical data that have now been obtained show that BT-061 reinforces the function of regulatory T-cells derived from MS patients.
´We are very pleased that the data now available confirm our expectations that the immunomodulatory mechanism of action of BT-061 has considerable potential in the indication MS, ´ comments Dr. Frank Osterroth, director of the Biotherapeutics Division at Biotest, on the data. ´Particularly in MS, there is still a significant medical need for effective and better tolerated and safe active agents despite modern approved products´.
***********************************************************
“Providing You with ‘MS Views and News’, is what we do“
Keep Informed and up–to–date with information concerning
Multiple Sclerosis when registered at
the MS Views and News website.
****************************************************************
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
. ****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews